Modelling patterns of clearance of HPV-16 infection and vaccination efficacy (Q43946877)

28 November 2017

title

Modelling patterns of clearance of HPV-16 infection and vaccination efficacy (English)

1 reference

28 November 2017

3

1 reference

28 November 2017

5

Paolo Vineis

1 reference

28 November 2017

Iacopo Baussano

1

1 reference

28 November 2017

Geoff Garnett

series ordinal

2

1 reference

28 November 2017

Guglielmo Ronco

series ordinal

4

1 reference

28 November 2017

language of work or name

English

0 references

publication date

8 December 2010

1 reference

28 November 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

28 November 2017

volume

29

1 reference

28 November 2017

issue

6

1 reference

28 November 2017

page(s)

1270-1277

1 reference

Epidemiology of Acquisition and Clearance of Cervical Human Papillomavirus Infection in Women from a High‐Risk Area for Cervical Cancer

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.082

Natural history of cervicovaginal papillomavirus infection in young women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.082

A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.082

Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.082

Regression of low-grade squamous intra-epithelial lesions in young women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.082

The natural history of human papillomavirus infection and cervical intraepithelial neoplasia among young women in the Guanacaste cohort shortly after initiation of sexual life.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.082

Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.082

Human papillomavirus and cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.082

Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.082

Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.082

Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.082

Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.082

Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.082

Interaction of human papillomaviruses with the host immune system: a well evolved relationship.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.082

Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.082

Natural history of human papillomavirus type 16 virus-like particle antibodies in young women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.082

A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.082

Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.082

Persistence of genital human papillomavirus infection in a long-term follow-up study of female university students.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.082

Cell-mediated immune response to human papillomavirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.082

An introduction to mathematical models in sexually transmitted disease epidemiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.082

Epidemiology and control and curable sexually transmitted diseases: opportunities and problems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.082

The use of mathematical models in the epidemiological study of infectious diseases and in the design of mass immunization programmes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.082

HPV-16 infection and cervical cancer: modeling the influence of duration of infection and precancerous lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.082

Third Italian national survey on knowledge, attitudes, and sexual behaviour in relation to HIV/AIDS risk and the role of health education campaigns

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.082

International incidence rates of invasive cervical cancer before cytological screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.082

Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.082

Evaluating human papillomavirus vaccination programs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.082

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.082

Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.082

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.082

Estimating progression rates for human papillomavirus infection from epidemiological data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.082

Social desirability bias in dietary self-report may compromise the validity of dietary intake measures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.082

Detection of human papillomavirus type 16 DNA in consecutive genital samples does not always represent persistent infection as determined by molecular variant analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.082

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2010.11.082

1 reference

28 November 2017

1 reference